British multinational pharmaceutical company GlaxoSmithKline (NYSE: GSK) declared in its last quarterly earnings call that the company’s integration and restructuring programs are on track, and sales are benefiting from recent new product introductions and most products recently acquired.

So much so, that the company says it will meet its guidance for 2015 and core EPS percentage growth will hit double digits in 2016.  Looking at its global businesses, GSK saw strong pro forma growth in its vaccines (+13%) and consumer healthcare business (+7%) in the U.S., Europe and its international business, whereas pro forma growth in its Pharmaceuticals business experienced overall weakness (1%+) as a result of pricing/generic competition, primarily. But progress on new product launches, the company believes, will offset these declines. With a dividend yield of 6.1%, GSK is a Buy up to $54

Europe’s biggest bank, HSBC (NYSE: HSBC), has shown its “resilience against a tough market backdrop,” to quote the CEO. The bank managed to post quarterly profits before tax that were 32% higher than the third quarter of 2014, even as Asia, one of its biggest markets, was hurt by falling stock markets and slowing economic growth.

Of course, the bank didn’t completely escape unscathed, revenues fell 4% as a result of the Asian markets collapse. In particular, management said the stock market correction in Asia affected principal retail banking and wealth management divisions.

The only silver lining in all of this, HSBC bankers said, was credit quality in Asia remained unscathed. Meanwhile, the bank was able to offset the weakness in Asia and increased regulatory compliance costs by lower fines on past misconduct.

 The firm, which a few months ago unveiled a “pivot to Asia” strategy designed to boost lackluster performance, has understandably put these plans on hold. The CEO recently noted “if the macro environment deteriorates (and the bank doesn’t further expand into Asia), we will clearly consider returning any excess capital to shareholders.”  With a dividend yield of 6.4%, HSBC is a Buy up to $55

Banco Santander (NYSE: SAN), one of Europe’s most globally diversified banks, reported a profit of 1.68 billion Euros for the third quarter, a 4% increase over the second quarter, excluding the impact of exchange rates. Gross income for the quarter was up 2%, as a result of growth in net interest income (moderate growth in business in some countries), fee income and normalization of gains on financial transactions.

On the balance sheet, management reports a continuing trend of growth as seen over the last few quarters. Lending is going up year-on-year. In the quarter, SAN grew loans 1% and deposits and mutual funds were also 1%. On a yearly basis, SAN is growing at 7%, as it reported at its Investor Day. Brazil remains Santander’s biggest market by revenue, accounting for one-quarter of group gross income and one-fifth of profits, which has been a source of concern for investors given the recession.

But the company’s Brazilian unit has managed well in this environment, given its conservative lending standards. As expected, improvements to the economy in the United Kingdom resulted in the greatest contribution to profits over the last 9 months, up 14% compared with the prior year on constant currency terms. With a dividend yield of 4.2%, SAN is a Buy up to $10.